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ABSTRACT
Background: Plasma membrane fluidity of poly-
morphonuclear leukocytes (PMN) was investigated in
10 allergic asthmatic children before and after oxato-
mide treatment.
Methods: Membrane fluidity was studied by mea-
suring the steady state fluorescence anisotropy of
1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexa-
triene (TMA-DPH) incorporated into polymorphonuclear
leukocyte (PMN) plasma membranes.
Results: There was an increase in membrane fluidity
at the surface of PMN from asthmatic children.
Oxatomide treatment significantly decreased PMN
membrane fluidity.
Conclusions: These data suggest that oxatomide
may induce changes in the physicochemical properties
of the PMN plasma membrane in asthmatic subjects.
These changes may modify the functional activities of
PMN.
Key words: bronchial asthma, leukocyte, membrane
fluidity, oxatomide.
INTRODUCTION
Since the introduction of oxatomide, a second-
generation histamine H1 receptor antagonist, clinical and
experimental data have provided a better understanding
of its efficacy, safety and mode of action. Oxatomide is
effective in the treatment of allergic rhinitis, urticaria and
atopic dermatitis.1–4 Moreover, there is now evidence that
it may be useful in the treatment of asthma.5
Various studies have demonstrated that oxatomide
possesses a variety of anti-inflammatory activities beyond
H1 receptor antagonism. Several in vitro and in vivo
studies performed on different cell types involved in
inflammation have demonstrated that oxatomide modu-
lates the inflammatory response. In particular, it has been
shown that oxatomide reduces epithelial intercellular
adhesion molecule (ICAM)-1 expression6 and inhibits 
the release of histamine, leukotriene C4 and tryptase by
basophils and mast cells,7 activation of the reduced
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase system in polymorphonuclear leukocytes (PMN),8
extracellular calcium influx in a mast cell model9 and 
the release of inflammatory mediators and agents from 
PMN and human lung tissue.10,11 The mechanisms by
which oxatomide acts remain unknown.
The plasma membrane is a focal point for the control
of cellular activity. Cell membranes act as macromolecu-
lar assemblies that respond to both internal and external
changes and integrate enzymatic responses and
functions, as well as sensitivities to other stimuli, by
rearrangement of membrane configuration and, in some
cases, also by altered composition.12 In the present study,
we evaluated the effect of oxatomide treatment on
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Ten children with mild allergic asthma (six females and
four males; age range 7.4–11.3 years; mean (±SD) age
9.4 ± 2.0 years) were included in the study after appro-
priate informed consent had been obtained. Patients
were selectively allergic to rye grass. The study was not
performed during the pollen season. Oxatomide in liquid
formulation, 15 mg twice daily, was administered for 
14 days. Patients were not permitted to take other anti-
histamines or systemic or inhaled anti-inflammatory
drugs. Patients were allowed to use salbutamol as rescue
medication in case of asthma exacerbation.
The control group consisted of 10 healthy children 
(five females and five males; age range 6.8–11.3 years;
mean age 9.7 ± 1.9 years). None of the children in the
control group had a family or personal history of allergy,
asthma or immunologic disorders. Adequate informed
consent was obtained from all subjects enrolled in the
study.
All subjects were without signs of acute infection at the
time of the study.
After overnight fasting, 10 mL heparinized blood was
obtained for PMN isolation. Simultaneously, we mea-
sured blood cholesterol, triglycerides and phospholipids.
Isolation of PMN
Polymorphonuclear leukocytes were separated using a
MonoPoly resolving Medium (ICN Biomedicals, Aurora,
OH, USA), as described previously.13 Cells were resus-
pended in Krebs’–Ringer phosphate (KRP) solution
supplemented with 5 mmol/L glucose.
Chemiluminescence measurements
Luminol-amplified chemiluminescence was measured in
the Autolumat LB 953 (Berthold, Wilbad, Germany) and
PMN were activated by the addition of 10–6 mol/L
phorbol myristate acetate (PMA; Sigma Chemical Co., 
St Louis, MO, USA). Chemiluminescence measurements
were taken over the next 60 min, as described previ-
ously.14 Chemiluminescence was measured as counts per
minute (c.p.m.).
Fluorescence measurements
Polymorphonuclear leukocytes were labeled in the dark.
1-[4-Trimethylammoniumphenyl]-6-phenyl-1,3,5-hexa-
triene (TMA-DPH; Molecular Probes, Eugene, OR, 
USA) was added to a 2.5 mL quartz cuvette containing
106 cells/mL PMN in 2 mL KRP, to give a final concentra-
tion of 10–6 mol/L TMA-DPH. Steady state fluorescence
anisotropy (rs) measurements were performed at 37°C
with a spectrofluorimeter (model MPF-66; Perkin Elmer,
Seer Green, UK) equipped with a Perkin Elmer personal
computer (model 7300) for data acquisition and elabo-
ration using TMA-DPH as the fluorescent probe, as
described previously.15,16 The computer program cal-
culated fluorescence anisotropy using the following
equation:
(I|| – I⊥ × g)/(I|| + (2I⊥ × g))
where g is an instrumental correction factor and I|| and I⊥
are the emission intensities with the polarizers parallel
and perpendicular to the direction of the polarized excit-
ing light, respectively.
RESULTS
During the treatment period none of the asthmatic chil-
dren used the rescue medication. Blood cholesterol
values, triglycerides and phospholipids from the control
and asthmatic groups were not significantly different 
(P > 0.5). Luminol-amplified chemiluminescence was
used, as described previously,15 to verify that, in isolated
PMN, the NADPH oxidase system is dormant under
resting conditions and can be activated by PMA. All
samples used in the present study demonstrated an acti-
vatable NADPH oxidase system. Peak activity was noted
within 15–20 min of addition of PMA and there was no
significant difference in the peak value of PMA-stimulated
chemiluminescence between the two groups ((7.94 ±
0.68 vs 8.10 ± 0.82) ×107 c.p.m., respectively). These
data indicate that PMN in both groups, asthmatic and
control children, were under resting conditions.
The background phospholipid fluorescence of PMN
was checked prior to each measurement and was less
than 0.1% of the fluorescence when TMA-DPH was
added. The fluorescence intensity of the free probe in KRP,
in the absence of PMN, was negligible.
Table 1 shows rs values in the control and asthmatic
groups before and after oxatomide treatment. In the asth-
matic group, rs values of TMA-DPH in the PMN were
significantly lower than in the control group. Treatment
with oxatomide induced a significant increase in rs values
in the asthmatic group.
DISCUSSION
Although PMN are not the dominant cells in asthma and
allergic diseases, they contribute to the inflammatory
process underlying the disease. Thus, PMN are increased
in bronchial biopsies, as well as in airway washings from
asthmatic subjects.17 Moreover, several inflammatory
mediators involved in asthma can prime or activate PMN.
Leukocyte–endothelial adhesion molecules are involved
in the recruitment and migration of inflammatory leuko-
cytes from the circulation to sites of inflammation.
Polymorphonuclear leukocytes are believed to play an
important role in several models of airway hyperactivity.17
Metzger et al. reported that superoxide generation by
PMN from asthmatics correlates with the severity of
bronchial constriction.18
Biological membranes are highly heterogeneous. They
consist of mixtures of different lipids and a variety of
different proteins. Different organizational modes of
compositionally and functionally differentiated domains
correspond to different physicochemical states of the
membrane.19 Many biological processes and biochemi-
cal events originate directly or indirectly within the cell
membrane. Chemical and physical events that take place
within the membrane allow the cells to carry out their
specific functions.20
Fluorescence spectroscopy encompasses a diverse set
of techniques capable of probing a wide range of fun-
damentally different physical, chemical and biological
processes. Fluorescence spectroscopy has been demon-
strated to be a useful tool in the study of the structure and
dynamics of biological membranes. This technique offers
several advantages for the study of membranes. Among
these advantages are the high sensitivity and virtual
absence of perturbation of membrane structure due to
the probes themselves. Also important is the responsive-
ness of the fluorescence parameters to the physical
properties of the environment and the possibility of
resolving spectroscopic parameters arising from sample
heterogeneity. Particularly interesting are those probes
with environmentally sensitive steady state fluorescence
parameters.21,22 1,6-Diphenyl-1,3,5-hexatriene (DPH) is
one such probe and a number of derivatives of DPH have
become popular as fluorescent probes in membrane
research. In particular, TMA-DPH has been used exten-
sively for studying membrane structure and fluidity
because of its advantageous structural and photo-
chemical properties. TMA-DPH is incorporated into the
membrane, but remains at the lipid–water interface
region because of its cationic residue. The rs of TMA-DPH
reflects the packing of the membrane lipid fatty acid
chain and can be related to the order parameter S, 
if certain precautions are taken. Lipid fluidity may be
defined as the reciprocal of the lipid structural order 
S and, thus, an increase in the TMA-DPH rs value cor-
responds to a decrease in membrane fluidity.23,24
In the present study, we observed that the rs value for
PMN from the asthmatic group was significantly lower
than in the control group. This indicates an increase in
membrane fluidity, which reflects a decrease of the lipid
order in the exterior part of the membrane. Although the
origin of this alteration is not known yet, we can speculate
that the inflammatory process induces these changes.
After oxatomide treatment, a significant increase in rs
value was observed, indicating a decrease in fluidity of
the plasma membrane. This observation suggests that
oxatomide may interact with the plasma membrane of
PMN. Oxatomide is a lipophilic molecule and, thus,
could interact with the lipid bilayer. A recent study by
Fischer et al.25 has demonstrated that oxatomide is able
to interact with plasma membrane lipid components,
although we cannot exclude the possibility that oxato-
mide acts indirectly by reducing the influence of
inflammatory processes on PMN.
Numerous studies have demonstrated that asthma is
associated with alterations in plasma membrane com-
position, function and fluidity of various cell types,
including leukocytes.26–29 Evidence has accumulated that
anti-inflammatory drugs can exert their action by interact-
ing with the plasma membrane of inflammatory cells.
Steroids are lipophilic, suggesting that they may inter-
calate into the bilayer of target cell plasma membranes,
potentially altering the fluidity and function of the
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Table 1 Mean ± SD of fluorescence anisotropy, rs, of 
1-(4-trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene 
at 37°C in polymorphonuclear leukocytes from control and
asthmatic children before and after oxatomide treatment
Control (n = 10) Asthmatic (n = 10)
Before treatment After treatment
rs 0.287 ± 0.003 0.255 ± 0.004* 0.276 ± 0.002**
*P < 0.001 compared with polymorphonuclear leukocytes (PMN)
from the control group; **P < 0.001 compared with PMN from the
asthmatic group before treatment.
membrane.30 Lamche et al. demonstrated that steroids
cause a decrease in membrane fluidity of PMN.31
Recently, we have demonstrated that nedocromil sodium
can induce changes in membrane fluidity of PMN plasma
membrane.32 These changes can induce functional
changes in the PMN from asthmatic subjects.
The present study demonstrates that oxatomide
treatment affects the physicochemical properties of
PMN plasma membranes in asthmatic subjects. These
changes may induce functional modifications of PMN.
The plasma membrane is a complex structure exhibiting
specific and dynamic interactions between its con-
stituents. Experimental evidence indicates that each
integral membrane protein interacts with its neighboring
‘boundary’ lipids in a specific manner.12 Changes in the
composition of this lipid boundary may lead to changes
in enzyme activity, as well as ligand specificity and affin-
ity.33 In contrast, functional activities of membrane
proteins are associated with changes in the composition
and organization of boundary lipids.34
Further studies investigating the effect of oxatomide on
plasma membrane fluidity of PMN could elucidate the
anti-inflammatory activiy of this drug in asthma.
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